Prostaglandin Reductase Detection and Activity Profiling

Comprehensive Prostaglandin Reductase Detection and Activity Profiling for Inflammatory Research, Drug Discovery, and Clinical Diagnostics

Prostaglandin reductase (also known as prostaglandin dehydrogenase or 15-hydroxyprostaglandin dehydrogenase, 15-PGDH) is a key enzyme in the catabolism of prostaglandins, catalysing the oxidation of the 15(S)-hydroxyl group to a 15-keto group, which dramatically reduces their biological activity. This enzyme plays a pivotal role in modulating the levels of bioactive prostaglandins, including prostaglandin E₂ (PGE₂), thereby influencing inflammation, pain, fever, and vascular function. Dysregulation of prostaglandin reductase activity is implicated in numerous pathological conditions, including cancer, chronic inflammatory diseases, and cardiovascular disorders. Consequently, the accurate and comprehensive detection of prostaglandin reductase—in terms of enzyme activity, protein abundance, kinetic parameters, and inhibition profiles—is indispensable for drug discovery, mechanistic research, and biomarker development. Our specialised detection platform provides a fully validated suite of biochemical and molecular assays tailored to prostaglandin reductase, delivering the high‑precision, actionable data that clients require to accelerate research, optimise drug candidates, and support regulatory submissions.

Understanding the Client's Need for Prostaglandin Reductase Analysis

Clients seeking prostaglandin reductase detection services are motivated by a range of strategic objectives. In drug discovery and development, the primary need is to quantify enzyme activity and to evaluate the inhibitory potency of novel compounds, to identify lead candidates for the treatment of inflammatory diseases, pain, or cancer. In mechanistic research, characterising the kinetic properties (K_m, V_max, k_cat) and the effect of post‑translational modifications on enzyme function is critical for understanding its regulatory role in prostaglandin metabolism. In clinical diagnostics and biomarker studies, measuring prostaglandin reductase expression or activity in patient‑derived samples (e.g., tissue biopsies, plasma) can provide insights into disease progression and therapeutic response. In quality control of biological reagents, verifying the activity and purity of recombinant or native prostaglandin reductase used in research is essential to ensure assay reproducibility. In regulatory submissions, comprehensive data on enzyme inhibition, selectivity, and stability are often required for IND and NDA filings. Our service is architected to address these diverse needs with a flexible, ISO 17025‑accredited analytical framework that adapts to the specific enzyme source (recombinant, tissue‑derived), substrate type, and client's research or regulatory context.

Integrated Analytical Platform for Holistic Prostaglandin Reductase Characterisation

Our analytical platform comprises four interconnected modules that collectively deliver a complete functional and molecular profile of any prostaglandin reductase sample. The Activity Quantification Module employs a well‑validated, continuous spectrophotometric assay using NAD⁺ or NADP⁺ as cofactor, monitoring the reduction of the cofactor at 340 nm, or a fluorescent assay using NAD(P)H as a substrate. We determine the specific activity (U/mg protein) with precision within ±3% RSD and a limit of detection (LOD) as low as 0.01 mU/mg. For detailed kinetic characterisation, we calculate Michaelis‑Menten parameters (K_m for PGE₂ and NAD⁺, V_max) with 95% confidence intervals typically within ±5%. For high‑throughput screening, we offer a fluorescence‑based assay using a NAD(P)H‑coupled substrate, with a Z’‑factor > 0.7. The Protein Quantitation Module uses ELISA with isoform‑specific antibodies (e.g., anti‑15‑PGDH, anti‑CRABP2), providing LOQs of 0.05 ng/mg of total protein and inter‑assay precision < 5%. For absolute quantitation without antibodies, we use LC‑MS/MS‑based targeted proteomics (PRM) with stable isotope‑labelled peptide standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous quantitation of multiple isoforms. The Inhibition and Drug Interaction Module evaluates the effect of test compounds on prostaglandin reductase activity using our validated substrate assay. We provide IC₅₀ values, mechanism‑of‑action analysis (competitive, uncompetitive, mixed), and binding affinity measurements by surface plasmon resonance (SPR), with K_D values in the low nM range. The Stability Module assesses enzyme stability under different storage conditions (temperature, pH, freeze‑thaw) and monitors activity retention over time, providing shelf‑life predictions using Arrhenius modelling. All modules are validated with reference prostaglandin reductase standards (recombinant or purified from natural sources) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Insight

Our platform consistently delivers performance that surpasses typical industry standards. In activity assays, we achieve signal‑to‑noise ratios > 200:1 at LOD, and our kinetic fitting software uses global non‑linear regression to provide precise estimates of K_m and V_max, with residual errors < 3%. For protein quantitation by PRM, our chromatographic gradient resolves isoform‑specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 4%. In inhibition studies, we perform full dose‑response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish‑Bowden analyses to determine the mechanism of inhibition. Additionally, we offer isothermal titration calorimetry (ITC) to measure the binding thermodynamics of inhibitors, providing ΔH, ΔS, and binding stoichiometry with precision within ±2%. For clients requiring detailed structural characterisation, we perform hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) to map inhibitor‑induced conformational changes, and X‑ray crystallography (where feasible) for detailed structural insights. This multi‑dimensional data set enables our clients to not only quantify enzyme activity but also to understand the molecular basis of inhibition, facilitating the rational design of more potent and selective compounds.

Distinctive Advantages of Our Prostaglandin Reductase Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix‑specific sample preparation protocols for a wide variety of prostaglandin reductase sources—including recombinant enzymes, tissue homogenates, cell lysates, and clinical samples—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of prostaglandin reductase isoforms, known inhibitors, and substrate analogues, enabling rapid method setup and benchmarking. Third, we offer a rapid screening service using a fluorogenic substrate assay that provides semi‑quantitative activity data within 4 hours of sample receipt—ideal for hit identification, lead optimisation, and early ADME profiling. Fourth, our customised drug interaction studies can be tailored to simulate physiological conditions, including the use of plasma protein binding and tissue‑specific cofactors to predict in vivo efficacy. Fifth, we provide integrated data interpretation that links enzyme activity, protein abundance, and inhibition profiles to biological outcomes (e.g., prostaglandin levels, inflammatory markers), enabling clients to prioritise compounds with desirable pharmacodynamic profiles. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on drug metabolism and bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by global regulatory authorities. Our team of pharmacologists, enzymologists, and mass spectrometrists provides consultative interpretation, helping clients to design follow‑up experiments, predict in vivo pharmacodynamics, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision‑making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, IC₅₀, mechanism of inhibition, protein abundance) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, kinetic fits, and SPR sensorgrams; (iii) a statistical comparison of samples against reference standards or historical data, with p‑values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a low IC₅₀ value indicates a potent inhibitor, or how a mixed‑type inhibition suggests a novel binding site. For clients with multiple compounds or donor samples, we provide multivariate analysis (PCA, PLS‑DA) to identify the most influential parameters and to guide compound selection. We also offer predictive models that estimate in vivo efficacy or toxicity based on in vitro enzyme inhibition data, using our internally developed pharmacokinetic‑pharmacodynamic (PK‑PD) modelling tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re‑analysis capability.

Broad Applications Across Drug Discovery, Clinical Pharmacology, and Inflammatory Research

The versatility of our prostaglandin reductase detection service spans a wide range of sectors. In pharmaceutical and biotech R&D, our assays are critical for lead optimisation, candidate selection, and off‑target profiling. In clinical pharmacology and therapeutics, our quantification of prostaglandin reductase in patient samples supports personalised medicine and biomarker discovery. In inflammatory disease research, our detailed kinetic and inhibition data help unravel the role of this enzyme in conditions such as arthritis, colitis, and cancer. In academic research, our comprehensive profiling supports publication‑quality studies on enzyme regulation and signal transduction. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. In quality control of biological products, we verify the activity of prostaglandin reductase used in commercial assay kits and reference materials. Our ability to tailor the analytical package to the specific enzyme source, substrate class, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing prostaglandin reductase analytics through continuous technological improvement. Our current R&D includes the development of high‑content, multiplexed activity assays using microfluidic chips for simultaneous measurement of multiple isoforms, and the application of machine learning algorithms to predict inhibition potency from chemical structure. We actively participate in inter‑laboratory proficiency testing for enzyme activity and protein analysis, and we contribute to the development of reference standards for prostaglandin metabolism. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 2 business days for rapid screening to 12 business days for comprehensive kinetic, inhibition, and proteomic profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance drug development and clinical research. We invite you to partner with us to unlock the full potential of your prostaglandin reductase research.

In summary, our prostaglandin reductase detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates enzyme activity, protein quantitation, inhibition profiling, and stability assessment. By combining advanced instrumentation with deep expertise in inflammatory pharmacology and enzymology, we empower our clients to accelerate drug discovery, understand disease mechanisms, and improve patient outcomes. We look forward to supporting your prostaglandin reductase analysis needs with our state‑of‑the‑art analytical platform.